Loading
The Chinese trial behind zevor-cel's approval for multiple myeloma, showing deep and lasting responses with a fully human BCMA CAR-T.
Phase 1/2 single-arm study at Chinese centres; the phase 2 report (Experimental Hematology and Oncology 2025) described high overall and complete response rates, deep minimal residual disease negativity and predominantly low-grade cytokine release syndrome. Basis of NMPA approval in February 2024. A parallel North American study (LUMMICAR STUDY 2) was run by CARsgen before it refocused on China.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
102 enrolled.
102 infused of 125 apheresed; median follow-up 20.3 months; DOR, PFS and OS not mature
SourceA further 2.9% reached complete response
SourceGrade 3-4 in 6.9%; ICANS in 2 patients, both grade 1
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective response rate (independent review committee)primary | Zevorcabtagene autoleucel | 102 | 92.2% | - | - | link |
| Stringent complete response | Zevorcabtagene autoleucel | 102 | 68.6% | - | - | link |
| Cytokine release syndrome, any grade | Zevorcabtagene autoleucel | 102 | 90.2% | - | - | link |
Shares Zevorcabtagene autoleucel, CARsgen Therapeutics, BCMA, CAR-T cell therapy and the tag china.
Shares Zevorcabtagene autoleucel, CARsgen Therapeutics, CAR-T cell therapy and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares CARsgen Therapeutics, CAR-T cell therapy and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares CARsgen Therapeutics, CAR-T cell therapy and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares CAR-T cell therapy and the tag china.